Skip to main content

Advertisement

SpringerLink
Log in

The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2)

  • Original Paper
  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Thrombospondin (TSP)-1 and TSP-2 share similar structures and functions, including a remarkable antiangiogenic activity. We have previously demonstrated that a mechanism of the antiangiogenic activity of TSP-1 is the interaction of its type III repeats domain with fibroblast growth factor-2 (FGF2), affecting the growth factor bioavailability and angiogenic activity. Since the type III repeats domain is conserved in TSP-2, this study aimed at investigating whether also TSP-2 retained the ability to interact with FGF2. The FGF2 binding properties of TSP-1 and TSP-2 and their recombinant domains were analyzed by solid-phase binding and surface plasmon resonance assays. TSP-2 bound FGF2 with high affinity (Kd = 1.3 nM). TSP-2/FGF2 binding was inhibited by calcium and heparin. The FGF2-binding domain of TSP-2 was located in the type III repeats and the minimal interacting sequence was identified as the GVTDEKD peptide in repeat 3C, corresponding to KIPDDRD, the active sequence of TSP-1. A second putative FGF2 binding sequence was also identified in repeat 11C of both TSPs. Computational docking analysis predicted that both the TSP-2 and TSP-1-derived heptapeptides interacted with FGF2 with comparable binding properties. Accordingly, small molecules based on the TSP-1 active sequence blocked TSP-2/FGF2 interaction. Binding of TSP-2 to FGF2 impaired the growth factor ability to interact with its cellular receptors, since TSP-2-derived fragments prevented the binding of FGF2 to both heparin (used as a structural analog of heparan sulfate proteoglycans) and FGFR-1. These findings identify TSP-2 as a new FGF2 ligand that shares with TSP-1 the same molecular requirements for interaction with the growth factor and a comparable capacity to block FGF2 interaction with proangiogenic receptors. These features likely contribute to TSP-2 antiangiogenic and antineoplastic activity, providing the rationale for future therapeutic applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Carlson CB, Lawler J, Mosher DF (2008) Structures of thrombospondins. Cell Mol Life Sci 65:672–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Adams JC, Lawler J (2011) The thrombospondins. Cold Spring Harb Perspect Biol 3:a009712. https://doi.org/10.1101/cshperspect.a009712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Armstrong LC, Bornstein P (2003) Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63–71

    Article  CAS  PubMed  Google Scholar 

  4. Lawler PR, Lawler J (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2:a006627. https://doi.org/10.1101/cshperspect.a006627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Volpert OV, Tolsma SS, Pellerin S et al (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217:326–332. https://doi.org/10.1006/bbrc.1995.2780

    Article  CAS  PubMed  Google Scholar 

  6. Panetti TS, Chen H, Misenheimer TM et al (1997) Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med 129:208–216

    Article  CAS  PubMed  Google Scholar 

  7. Armstrong LC, Björkblom B, Hankenson KD et al (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893–1905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kyriakides TR, Zhu YH, Smith LT et al (1998) Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 140:419–430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kyriakides TR, Tam JW, Bornstein P (1999) Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787. https://doi.org/10.1046/j.1523-1747.1999.00755.x

    Article  CAS  PubMed  Google Scholar 

  10. Hawighorst T, Velasco P, Streit M et al (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640. https://doi.org/10.1093/emboj/20.11.2631

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kunstfeld R, Hawighorst T, Streit M et al (2014) Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis. J Dermatol Sci 74:106–115. https://doi.org/10.1016/j.jdermsci.2014.01.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sun R, Wu J, Chen Y et al (2014) Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer. Mol Cancer 13:225. https://doi.org/10.1186/1476-4598-13-225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tokunaga T, Nakamura M, Oshika Y et al (1999) Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79:354–359. https://doi.org/10.1038/sj.bjc.6690056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Oshika Y, Masuda K, Tokunaga T et al (1998) Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4:1785–1788

    CAS  PubMed  Google Scholar 

  15. Dvorkina M, Nieddu V, Chakelam S et al (2016) A Promyelocytic leukemia protein-thrombospondin-2 axis and the risk of relapse in neuroblastoma. Clin Cancer Res 22:3398–3409. https://doi.org/10.1158/1078-0432.CCR-15-2081

    Article  CAS  PubMed  Google Scholar 

  16. Chijiwa T, Abe Y, Ikoma N et al (2009) Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice. Int J Oncol 34:5–13

    CAS  PubMed  Google Scholar 

  17. Streit M, Riccardi L, Velasco P et al (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96:14888–14893

    Article  CAS  PubMed  Google Scholar 

  18. Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34. https://doi.org/10.1016/j.matbio.2004.11.005

    Article  CAS  PubMed  Google Scholar 

  19. Isenberg JS, Annis DS, Pendrak ML et al (2009) Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284:1116–1125. https://doi.org/10.1074/jbc.M804860200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Calabro NE, Kristofik NJ, Kyriakides TR (2014) Thrombospondin-2 and extracellular matrix assembly. Biochim Biophys Acta 1840:2396–2402. https://doi.org/10.1016/j.bbagen.2014.01.013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Resovi A, Pinessi D, Chiorino G, Taraboletti G (2014) Current understanding of the thrombospondin-1 interactome. Matrix Biol 37:83–91. https://doi.org/10.1016/j.matbio.2014.01.012

    Article  CAS  PubMed  Google Scholar 

  22. Margosio B, Marchetti D, Vergani V et al (2003) Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 102:4399–4406

    Article  CAS  PubMed  Google Scholar 

  23. Margosio B, Rusnati M, Bonezzi K et al (2008) Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 40:700–709

    Article  CAS  PubMed  Google Scholar 

  24. Taraboletti G, Belotti D, Borsotti P et al (1997) The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8:471–479

    CAS  PubMed  Google Scholar 

  25. Colombo G, Margosio B, Ragona L et al (2010) Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 285:8733–8742. https://doi.org/10.1074/jbc.M109.085605

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Annis DS, Murphy-Ullrich JE, Mosher DF (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459–468

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mosher DF, Huwiler KG, Misenheimer TM, Annis DS (2002) Expression of recombinant matrix components using baculoviruses. Methods Cell Biol 69:69–81

    Article  CAS  PubMed  Google Scholar 

  28. Amblard M, Fehrentz J-A, Martinez J, Subra G (2006) Methods and protocols of modern solid phase peptide synthesis. Mol Biotechnol 33:239–254. https://doi.org/10.1385/MB:33:3:239

    Article  CAS  PubMed  Google Scholar 

  29. Foglieni C, Pagano K, Lessi M et al (2016) Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep 6:23432. https://doi.org/10.1038/srep23432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pagano K, Torella R, Foglieni C et al (2012) Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS ONE 7:e36990. https://doi.org/10.1371/journal.pone.0036990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Misenheimer TM, Mosher DF (2005) Biophysical characterization of the signature domains of thrombospondin-4 and thrombospondin-2. J Biol Chem 280:41229–41235. https://doi.org/10.1074/jbc.M504696200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Misenheimer TM, Hannah BL, Annis DS, Mosher DF (2003) Interactions among the three structural motifs of the C-terminal region of human thrombospondin-2. Biochemistry 42:5125–5132

    Article  CAS  PubMed  Google Scholar 

  33. Carlson CB, Bernstein DA, Annis DS et al (2005) Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Mol Biol 12:910–914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kvansakul M, Adams JC, Hohenester E (2004) Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. Embo J 23:1223–1233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hannah BL, Misenheimer TM, Annis DS, Mosher DF (2003) A polymorphism in thrombospondin-1 associated with familial premature coronary heart disease causes a local change in conformation of the Ca2+-binding repeats. J Biol Chem 278:8929–8934

    Article  CAS  PubMed  Google Scholar 

  36. Hannah BL, Misenheimer TM, Pranghofer MM, Mosher DF (2004) A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding. J Biol Chem 279:51915–51922

    Article  CAS  PubMed  Google Scholar 

  37. Giacomini A, Chiodelli P, Matarazzo S et al (2016) Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy. Pharmacol Res 107:172–185. https://doi.org/10.1016/j.phrs.2016.03.024

    Article  CAS  PubMed  Google Scholar 

  38. Chiodelli P, Bugatti A, Urbinati C, Rusnati M (2015) Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules 20:6342–6388. https://doi.org/10.3390/molecules20046342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Rusnati M, Presta M (2015) Angiogenic growth factors interactome and drug discovery: the contribution of surface plasmon resonance. Cytokine Growth Factor Rev 26:293–310. https://doi.org/10.1016/j.cytogfr.2014.11.007

    Article  CAS  PubMed  Google Scholar 

  40. Rusnati M, Bugatti A, Mitola S et al (2009) Exploiting surface plasmon resonance (SPR) technology for the identification of fibroblast growth factor-2 (FGF2) antagonists endowed with antiangiogenic activity. Sensors (Basel) 9:6471–6503. https://doi.org/10.3390/s90806471

    Article  CAS  Google Scholar 

  41. Muppala S, Frolova E, Xiao R et al (2015) Proangiogenic properties of thrombospondin-4. Arterioscler Thromb Vasc Biol 35:1975–1986. https://doi.org/10.1161/ATVBAHA.115.305912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Annis DS, Gunderson KA, Mosher DF (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067–27075. https://doi.org/10.1074/jbc.M703804200

    Article  CAS  PubMed  Google Scholar 

  43. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116–129. https://doi.org/10.1038/nrc2780

    Article  CAS  PubMed  Google Scholar 

  44. Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437:199–213. https://doi.org/10.1042/BJ20101603

    Article  CAS  Google Scholar 

  45. Stenina-Adognravi O (2014) Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biol 37:69–82. https://doi.org/10.1016/j.matbio.2014.02.001

    Article  CAS  PubMed  Google Scholar 

  46. Tooney PA, Sakai T, Sakai K et al (1998) Restricted localization of thrombospondin-2 protein during mouse embryogenesis: a comparison to thrombospondin-1. Matrix Biol 17:131–143

    Article  CAS  PubMed  Google Scholar 

  47. Kyriakides TR, Maclauchlan S (2009) The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 3:215–225. https://doi.org/10.1007/s12079-009-0077-z

    Article  PubMed  PubMed Central  Google Scholar 

  48. Agah A, Kyriakides TR, Lawler J, Bornstein P (2002) The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161:831–839. https://doi.org/10.1016/S0002-9440(10)64243-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Murphy-Ullrich JE, Suto MJ (2017) Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biol. https://doi.org/10.1016/j.matbio.2017.12.009

    Article  PubMed  PubMed Central  Google Scholar 

  50. Schultz-Cherry S, Chen H, Mosher DF et al (1995) Regulation of transforming growth factor-b activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304–7310

    Article  CAS  PubMed  Google Scholar 

  51. Taraboletti G, Rusnati M, Ragona L, Colombo G (2010) Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1:662–673

    Article  Google Scholar 

  52. Koch M, Hussein F, Woeste A et al (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128:337–346. https://doi.org/10.1007/s10549-010-1085-7

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Supported by the Italian Association for Cancer Research (AIRC IG16833 to GT), Ministero dell’Istruzione, Università e Ricerca (MIUR, ex 60%) to MR.

Author information

Author notes

  1. Chiara Foglieni

    Present address: Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Torricella-Taverne, Switzerland

Authors and Affiliations

  1. Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, 25123, Italy

    Marco Rusnati, Paola Chiodelli, Giulia Paiardi & Antonella Bugatti

  2. Tumor Angiogenesis Unit, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Stezzano, 87, Bergamo, 24126, Italy

    Patrizia Borsotti, Chiara Foglieni, Laura Carminati, Denise Pinessi, Dorina Belotti & Giulia Taraboletti

  3. IRCCS MultiMedica, Milano, 20138, Italy

    Elisabetta Moroni

  4. Departments of Biomolecular Chemistry and Medicine, University of Wisconsin, Madison, WI, 53706, USA

    Douglas S. Annis & Deane F. Mosher

  5. Istituto di Chimica del Riconoscimento Molecolare, Consiglio Nazionale delle Ricerche (ICRM-CNR), Milano, 20131, Italy

    Alessandro Gori, Renato Longhi & Giorgio Colombo

  6. Dipartimento di Chimica, Università di Pavia, Pavia, 27100, Italy

    Giorgio Colombo

Authors
  1. Marco Rusnati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Borsotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabetta Moroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Foglieni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Chiodelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laura Carminati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Denise Pinessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Douglas S. Annis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giulia Paiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Antonella Bugatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alessandro Gori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Renato Longhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Dorina Belotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Deane F. Mosher
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Giorgio Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Giulia Taraboletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulia Taraboletti.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 2281 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rusnati, M., Borsotti, P., Moroni, E. et al. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis 22, 133–144 (2019). https://doi.org/10.1007/s10456-018-9644-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-018-9644-3

Keywords

Search

Navigation